Form 4: NewAmsterdam Pharma CEO Michael Davidson Buys 5,000 Shares
SEC Form 4 Filing
NewAmsterdam Pharma's CEO, Michael H. Davidson, recently acquired 5,000 ordinary shares of the company at an average price of $17.2617 per share.
Summary
- On June 20, 2024, Michael H. Davidson, CEO of NewAmsterdam Pharma Co N.V., purchased 5,000 ordinary shares.
- The shares were bought at a weighted average price of $17.2617, with individual transactions ranging from $17.115 to $17.60.
- Following this transaction, Davidson directly owns 204,784 ordinary shares.
- Davidson also has indirect beneficial ownership of 608,779 ordinary shares held by Stichting Administratiekantoor EPNAP (STAK EPNAP).
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase suggests confidence, but it's a relatively small transaction.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive signal, but should be considered alongside other factors.
Stakeholder Impact
- The share purchase could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of the share purchase transaction. |
| 06/24/2024 | Date of the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.